NSEPress Release6d ago · 3 Nov 2026, 11:28 am
Press Release
Gland Pharma Limited · GLAND
✦ AI Summary▲ PositiveM&A
Gland Pharma Limited has received approval from the USFDA for its Abbreviated New Drug Application filed for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials. The product had US sales of approximately USD 214 million for the twelve months ending August 2026.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment9/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Gland Pharma Receives Approval for Methylprednisolone Acetate Injectable Suspension USP, Single-Dose and Multiple-Dose Vials".